SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.
IPO Year:
Exchange: NASDAQ
Website: seaspine.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $12.00 → $6.75 | Buy → Hold | Truist |
| 4/22/2022 | $27.00 → $21.00 | Overweight | Cantor Fitzgerald |
| 4/13/2022 | $20.00 | Buy | Truist |
| 12/21/2021 | $25.00 → $20.00 | Buy | Truist Securities |
| 10/28/2021 | $100.00 | Buy | Loop Capital |
SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)
SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)
SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)
SC 13G/A - SeaSpine Holdings Corp (0001637761) (Subject)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
4 - SeaSpine Holdings Corp (0001637761) (Issuer)
CT ORDER - SeaSpine Holdings Corp (0001637761) (Filer)
15-12G - SeaSpine Holdings Corp (0001637761) (Filer)
EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)
EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)
EFFECT - SeaSpine Holdings Corp (0001637761) (Filer)
25-NSE - SeaSpine Holdings Corp (0001637761) (Subject)
8-K - SeaSpine Holdings Corp (0001637761) (Filer)
8-K - SeaSpine Holdings Corp (0001637761) (Filer)
425 - SeaSpine Holdings Corp (0001637761) (Subject)
425 - SeaSpine Holdings Corp (0001637761) (Subject)
CARLSBAD, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing fru
Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221118005106/en/ Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Sen
LEWISVILLE, Texas and CARLSBAD, Calif., Nov. 18, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic will serve as Chief Financial Officer (CFO) for the new combined company, effective upon the completion of their pending merger. Bostjancic currently serves as the CFO and Chief Operating Officer of SeaSpine, roles he has held since 2015 and 2022 respectively. Previously, Bostjancic served as Treasurer and Senior Vice President from 2015 through 2022, and as
CARLSBAD, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will present at the upcoming Stifel 2022 Healthcare Conference. Members of management are scheduled to present on Wednesday, November 16, 2022 at 12:35 p.m. Pacific time / 3:35 p.m. Eastern time. Interested parties can access a live webcast of the presentation directly by following this link. An archived webcast of the presentation will be available on the Investors section of the SeaSpine website at https://investor.seaspine.com/ About SeaSpineSeaSpine (ww
CARLSBAD, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today financial results for the third quarter of 2022. Summary Third Quarter 2022 Financial Results and Recent Highlights Total revenue of $67.1 million, an increase of 45% year-over-yearU.S. revenue of $51.1 million, an increase of 24% year-over-yearU.S. spinal implants and enabling technologies revenue of $27.4 million, an increase of 30% year-over-yearU.S. orthobiologics revenue of $23.8 million, an increase of 18% year-over-yearInternational revenue of $16.0 million, an incre
CARLSBAD, Calif., Oct. 31, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Mariner® MIS Wayfinder System. Mariner MIS Wayfinder is a novel, one step, k-wireless screw delivery system for pedicle screw fixation. Mariner MIS Wayfinder eliminates reliance on traditional guidewires for percutaneous screw placement by providing a fully integrated, surgeon-led solution that leverages the strength and versatility of SeaSpine's foundational Mariner modular pedicle screw technology. Mariner MIS Wayfinder
CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des
CARLSBAD, Calif., Oct. 18, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the 7D FLASH™ Navigation System Percutaneous Spine Module. The release of the Percutaneous Module represents a new application and increased functionality for its 7D FLASH Navigation System, which now allows SeaSpine to further penetrate the minimally invasive spine surgery market, which SeaSpine estimates at approximately $4 billion worldwide. "The addition of the Percutaneous Module to the FLASH Navigation System has brought versatility to my
CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today preliminary financial results for the third quarter of 2022. Preliminary and Unaudited Third Quarter 2022 Financial Results Total revenue is expected to range from $66.7 to $67.2 million, reflecting 44% to 45% year-over-year growthU.S. revenue is expected to range from $50.9 to $51.2 million, reflecting 23% to 24% year-over-year growth U.S. spinal implants and enabling technologies revenue is expected to reflect 29% to 30% year-over-year growthU.S. orthobiologics revenue i
Third quarter net sales of $114 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year Global Orthopedics net sales growth of 19% on a constant currency basis driven by commercial channel investments Biologics net sales growth of 8% driven by new product introductions Bone Growth Therapies net sales growth of 3% driven by the commercial roll-out of AccelStim™ Bone Healing Therapy Announced agreement to merge with SeaSpine Holdings Corporation (NASDAQ:SPNE, SeaSpine", ))), creating a leading global spine and orthopedics company Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited third quarter 2022 net sales of appro
Truist downgraded SeaSpine from Buy to Hold and set a new price target of $6.75 from $12.00 previously
Cantor Fitzgerald resumed coverage of SeaSpine with a rating of Overweight and set a new price target of $21.00 from $27.00 previously
Truist resumed coverage of SeaSpine with a rating of Buy and set a new price target of $20.00
Truist Securities reiterated coverage of SeaSpine Holdings with a rating of Buy and set a new price target of $20.00 from $25.00 previously
Loop Capital initiated coverage of SeaSpine with a rating of Buy and set a new price target of $100.00
Canaccord Genuity reiterated coverage of SeaSpine Holdings with a rating of Buy and set a new price target of $30.00 from $28.00 previously
Wells Fargo upgraded SeaSpine Holdings from Equal-Weight to Overweight and set a new price target of $24.00
Canaccord Genuity reiterated coverage of SeaSpine with a rating of Buy and set a new price target of $25.00 from $23.00 previously
Canaccord Genuity reiterated coverage of SeaSpine with a rating of Buy and set a new price target of $25.00 from $23.00 previously
Piper Sandler reiterated coverage of SeaSpine with a rating of Overweight and set a new price target of $22.00 from $18.00 previously
CARLSBAD, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that John Bostjancic, previously the Company's Senior Vice President, Chief Financial Officer, has assumed expanded responsibilities and the title of Chief Operating and Financial Officer. In addition, the Company announced that Hollis Winkler joined the Company as Senior Vice President, Human Resources. With her hiring, Ms. Winkler joined the SeaSpine Senior Leadership Team. Mr. Bostjancic has served as SeaSpine's Chief Financial Officer since 2015. He has been an influentia
CARLSBAD, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the elevation of Dr. Frank Vizesi to Chief Scientific Officer and Shaeffer Bannigan to Vice President, Product Development, Spinal Implants. With his promotion, Mr. Bannigan joins the SeaSpine Senior Leadership Team. Dr. Vizesi joined SeaSpine in 2015 as Director, Research and Development, Orthobiologics. He quickly elevated the approach and defined the vision for delivering best-in-class orthobiologics procedural solutions. Under Dr. Vizesi's leadership, the team deepened
CARLSBAD, Calif., Dec. 14, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today that it has appointed Angela Steinway to its Board of Directors, effective December 14, 2021. Ms. Steinway will serve as a member of the company's Audit Committee. With the appointment of Ms. Steinway, the SeaSpine Board of Directors now consists of nine directors, eight of whom are independent. Ms. Steinway brings over 15 years of experience in the medical device industry, having worked in various strategy, sales and finance functions throughout her career. Currently, she i
DURHAM, N.C., July 06, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class yet more affordable cellular immunotherapies, today announced the appointments of Michael Fekete and Greg Tibbitts, to the Company's board of directors. Mr. Fekete and Mr. Tibbitts bring with them a wealth of financial, capital markets and strategic expertise, and prior board level experience. Mr. Fekete is an advisor and board member for companies in the pharmaceutical, biotechnology and medical device industries. His areas of expertise include business strategy, capital markets, M&A and corporate governance developed through 35
CARLSBAD, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it has appointed Shweta Singh Maniar to its Board of Directors, effective April 1, 2021. Ms. Maniar is a Global Leader, Healthcare & Life Sciences Solutions & Strategy, Google Cloud where she leads the visions, strategy and execution of Google Cloud’s industry product strategy and go-to-market model focused in Life Sciences. Keith C. Valentine, SeaSpine President and Chief Executive Officer, said: “Shweta is an exceptional complement to the 7D Surgical transaction
CARLSBAD, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Tuesday, November 1, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. To listen to the live webcast and a replay, please visit the Investors section of the SeaSpine website at: https://www.seaspine.com/. About SeaSpine SeaSpine (www.seaspine.com) is a global medical technology company focused on the des
Highly complementary spine and orthopedics portfoliosOne of the industry's broadest biologics and regenerative technology offeringsDifferentiated and synergistic enabling technologiesMeaningful cross-selling revenue synergies and cost savingsFinancial strength to pursue growth investments without need for immediate equity financing Expected to be adjusted EBITDA accretive to Orthofix by the second year following close including cost savings Companies to host joint conference call and webcast today at 8:00 a.m. ET LEWISVILLE, Texas and CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Orthofix (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpin
CARLSBAD, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today second quarter financial results for the three-months ended June 30, 2022. Summary Second Quarter 2022 Financial Results and Recent Highlights Total revenue of $56.3 million, an increase of 19% year-over-yearU.S. revenue of $49.5 million, an increase of 16% year-over-year U.S. spinal implants and enabling technologies revenue of $25.0 million, an increase of 17% year-over-yearU.S. orthobiologics revenue of $24.5 million, an increase of 16% year-over-year International reve
CARLSBAD, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Tuesday, August 2, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. Individuals interested in listening to the conference call may do so by registering here. Participants are required to register at a minimum 15 minutes before the start of the call. To listen to the live webcast and a replay, please visi
CARLSBAD, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release first quarter financial results after the close of trading on Tuesday, May 3, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 9979866. To listen to a live webcast, please visit the Inv
CARLSBAD, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today financial results for the three-months and full-year ended December 31, 2021. Summary Fourth Quarter 2021 Financial Results and Recent Accomplishments Revenue of $55.6 million, an increase of 20% year-over-yearU.S. revenue of $50.2 million, an increase of 19% year-over-year U.S. spinal implants and enabling technologies revenue of $27.3 million, an increase of 32% year-over-yearU.S. orthobiologics revenue of $22.9 million, an increase of 7% year-over-year International rev
CARLSBAD, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release fourth quarter and full year 2021 financial results on Friday, March 11, 2022. Members of the Company's management team will host a corresponding conference call and webcast beginning at 9:00 am PT / 12:00 pm ET and ending at 10:30 am PT / 1:30 pm ET. Concurrently, the Company will host a Virtual Analyst and Investor Day with financial analysts and institutional investors. With the completion of the 7D Surgical integration, the Company's management team
CARLSBAD, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced financial results for the three-months ended September 30, 2021. Summary of Third Quarter 2021 Financial Results and Recent Accomplishments Total revenue of $46.4 million, reflecting a 7.5% increase compared to 2020 and a 16.4% increase compared to the third quarter of 2019U.S. revenue of $41.2 million, reflecting a 5.5% increase compared to 2020 and a 16% increase compared to the third quarter of 2019 U.S. spinal implants and enabling technologies revenue of $21.1 million,
CARLSBAD, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release third quarter financial results after the close of trading on Thursday, October 28, 2021. Members of the Company's management team will host a corresponding conference call and webcast beginning at 1:30 pm PT / 4:30 pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 6699691. To listen to a live webcast, please visit th
CARLSBAD, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Monday, August 2, 2021. Members of the Company's management team will host a corresponding conference call and webcast beginning at 2:00 pm PT / 5:00 pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 1257053. To listen to a live webcast, please visit the
Orthofix and SeaSpine Stockholders Approve Merger Orthofix Medical Inc. (NASDAQ:OFIX) and SeaSpine Holdings Corporation today announced the successful completion of their previously announced merger of equals following the approval of each company's stockholders at respective special meetings of stockholders held today. Of votes cast, 99% of SeaSpine common shares were voted in approval of the merger, and 98% of Orthofix common shares were voted in approval of the merger. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230104005893/en/ The merger will officially become effective as of 12:01 a.m. Eastern Standard Time on January
SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the placement of its 100th 7D FLASH™ Navigation System globally. The 7D FLASH™ Navigation System uses visible light to create a three-dimensional image for surgical navigation in just seconds, which is expected to result in shorter and more efficient spinal procedures with less radiation exposure. It is the only marketed image-guidance system that utilizes novel and proprietary camera-based technology, coupled with machine-vision algorithms, to eliminate the long-standing frustrations with legacy surgical navigation platforms.
-SEC Filing
Upgrades According to Evercore ISI Group, the prior rating for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) was changed from In-Line to Outperform. In the third quarter, BioCryst Pharmaceuticals showed an EPS of $0.23, compared to $0.33 from the year-ago quarter. The current stock performance of BioCryst Pharmaceuticals shows a 52-week-high of $19.99 and a 52-week-low of $7.61. Moreover, at the end of the last trading period, the closing price was at $11.86. According to B of A Securities, the prior rating for KKR & Co Inc (NYSE:KKR) was changed from Neutral to Buy. In the third quarter, KKR & Co showed an EPS of $0.93, compared to $1.05 from the year-ago quarter. At the moment, the stock
Truist Securities analyst Richard Newitter downgrades SeaSpine Holdings (NASDAQ:SPNE) from Buy to Hold and lowers the price target from $12 to $6.75.
SeaSpine Holdings (NASDAQ:SPNE) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.30) by 40 percent. This is a 12.5 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $67.10 million which beat the analyst consensus estimate of $65.68 million by 2.16 percent. This is a 44.47 percent increase over sales of $46.45 million the same period last year.
Companies Reporting Before The Bell • BP (NYSE:BP) is estimated to report quarterly earnings at $2.07 per share on revenue of $64.76 billion. • Sony Group (NYSE:SONY) is estimated to report quarterly earnings at $1.28 per share on revenue of $18.04 billion. • Chunghwa Telecom (NYSE:CHT) is estimated to report earnings for its third quarter. • Blucora (NASDAQ:BCOR) is projected to report earnings for its third quarter. • Axcella Health (NASDAQ:AXLA) is likely to report earnings for its third quarter. • Kopin (NASDAQ:KOPN) is expected to report quarterly loss at $0.04 per share on revenue of $12.05 million. • Great Lakes Dredge & Dock (NASDAQ:GLDD) is expected to report quarterly earnin
SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the Mariner® MIS Wayfinder System. Mariner MIS Wayfinder is a novel, one step, k-wireless screw delivery system for pedicle screw fixation. Mariner MIS Wayfinder eliminates reliance on traditional guidewires for percutaneous screw placement by providing a fully integrated, surgeon-led solution that leverages the strength and versatility of SeaSpine’s foundational Mariner modular pedicle screw technology. Mariner MIS Wayfinder is fully integrated with the 7D FLASH™ Navigation System’s recentl
SeaSpine Holdings (NASDAQ:SPNE) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that SeaSpine Holdings will report an earnings per share (EPS) of $-0.30. SeaSpine Holdings bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Historical Earnings Performance Last quarter the company missed EPS by $0.03, which was followed by
SeaSpine Holdings Corporation (NASDAQ:SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of the 7D FLASH™ Navigation System Percutaneous Spine Module. The release of the Percutaneous Module represents a new application and increased functionality for its 7D FLASH Navigation System, which now allows SeaSpine to further penetrate the minimally invasive spine surgery market, which SeaSpine estimates at approximately $4 billion worldwide. "The addition of the Percutaneous Module to the FLASH Navigation System has brought versatility to my OR," stated Dr. Douglas Orndorff of Spine Colorado.